And that when they come back, they expect to come back in full and they will come back as the rates start to earn through and actually impact their underwriting profitability and that they are not going to front-run rate adequacy, well, full rate adequacy by cherry picking certain states where they already have rate increases to start to gradually get back into the marketplace. And so I think what we are going to expect to see as the year progresses is that, carriers will really need to establish broader profitability in order to then come back into the marketplace as a whole as opposed to starting to ease back into the market in those states where they feel good about their rates. Does that make sense, Andrew?
Andrew Kligerman: Yeah. Makes a lot of sense, Steve. Thanks so much.
Steve Yi: Sure.
Operator: Our next question comes from Daniel Grosslight with Citi.
Daniel Grosslight: Hi, guys. Thanks for taking the question. Congrats on the quarter. Let’s stick with the health segment here. So there’s been some chatter out there in the Medicare Advantage market about a potential slowdown given a less generous advance notice for plan year 2024, obviously, a lot is up in the air. But I am curious if you are hearing anything from your partners on that and if there are any leverage you can pull if you see a macro slowdown in Medicare Advantage?
Steve Yi: Yeah. I think that’s a great question. I mean I think it’s — the short answer is it’s too early to tell. These proposed rates, I think, came out fairly recently, like, I think, a couple of weeks ago and they won’t be finalized until April. And so as you know that there’s a healthy debate with the large Health Insurance companies in CMS on really the adequacy of the rate increases that they can expect for 2024. We have been in dialogue with our partners about that, and I think, universally, I think, the sentiment is that it’s really too early to tell.
Daniel Grosslight: Yeah. Yeah. Okay. And you mentioned that health growth is accretive to contribution margin in your shareholder letter. I was wondering if you could quantify how much better health contribution is than the rest of the business and what are some of the drivers of that accretion?
Pat Thompson: Yeah. The — I think in our financials, I think, you can kind of tease out some of those numbers. But the big difference, I would say, is that, on the health side, we have a much higher open marketplace mix and we have effectively a higher take rate on the open marketplace side. So revenue equals transaction value, and we have — the contribution as a percentage of transaction value is almost 3x the rate of the private marketplace. And so the mix is more favorable within the health side and so the take rate is quite a bit higher. And so that’s one of the reasons why Q4 is our biggest quarter, because it’s our biggest revenue quarter and it mixes to help.
Daniel Grosslight: Yeah. Makes sense. And then one just housekeeping question, there was a big increase in accounts receivable this quarter. I know it’s related. But I am curious if you can talk about what drove that and you are a little bit little on cash now, obviously, you are very efficient with that. But do you anticipate you will have to draw on your revolver and kind of what your working capital needs are in 2023?
